Patient Community Events

On Tuesday, September 18, 2018 from 4:00 to 5:00 p.m. Eastern Time, The Mastocytosis Society and Blueprint Medicines are hosting a webinar for the systemic mastocytosis (SM) community about avapritinib (also known as BLU-285), an investigational medicine for people with SM.

Dr. Andy Boral, Chief Medical Officer at Blueprint Medicines, will share an update on recently presented clinical results, as well as plans for future studies in advanced, indolent and smoldering forms of SM.

We invite people with SM and their families to participate, and to submit questions in advance for the Q&A portion of the webcast. Questions may be submitted to The Mastocytosis Society at research@tmsforacure.org or to Blueprint Medicines at patients@blueprintmedicines.com by Wednesday, September 12. When emailing a question, please include the subject line “Blueprint Patient Webinar.”

For thirty days following the event, a replay of the webcast will be made available in the “Patients” section of the Blueprint Medicines website under “Patient Community Events,” located at: http://www.blueprintmedicines.com/patients/patient-community-events. The archived webcast will be available on the site about one day after the call.

Informational Webcast on Avapritinib Clinical Trial Program in Systemic Mastocytosis

Date: Tuesday, September 18, 2018
Time: 4:00 to 5:00 p.m. Eastern Time

Webinar link: https://zoom.us/j/549167852

Dial-in for audio only: Toll +1 646-876-9923 , Tollfree +1 877-369-0926

Webinar ID: 549-167-852